In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Alcobra Ltd.

Tech Transfer Roundup: Athenex, PDS Align With National Cancer Institute On Oncology R&D

Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.

Tech Transfer Round-Up Deals

Arcturus Founder Reinstated As CEO As Settlement Ends Four-Month Feud With Former Board

The unexpected firing of Arcturus CEO Joseph Payne kicked off a bitter public battle for control of the RNA therapeutics firm after a reverse merger with Alcobra in November. The dispute now settled, the new board has reinstated Payne at Arcturus' helm.

Legal Issues Business Strategies

Biopharma Quarterly Dealmaking Statistics, Q3 2017

Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.

BioPharmaceutical Deals

Deal Watch: Neos Says ‘Thanks, No Thanks’ To Repeated PDL Offer

Daiichi teams with Glycotope on an antibody-drug conjugate for cancer, while Alector will partner with AbbVie to research antibody targets for Alzheimer’s disease.

Deals M & A
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Alcobra Pharma
    • Arcturus Therapeutics, Inc.
UsernamePublicRestriction

Register